IBD Evidence

Liječenje

Usporedba bioloških i naprednih terapija

Po prvi put, komparativno pitanje — koji lijek, a ne treba li lijek — ima meta-analitičke odgovore.

Updated 2 min read 26 citations Evidence strength 5/5

Žičana endoskopska omča koja se koristi za polipektomiju gornjeg gastrointestinalnog trakta i debelog crijeva
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Što se promijenilo

Dva desetljeća baza dokaza temeljila se na usporedbi lijeka i placeba, što je kliničarima govorilo da biološki lijekovi djeluju, ali ništa o tome koji odabrati. Mrežna meta-analiza to je promijenila korištenjem zajedničkih komparatora za neizravno rangiranje terapija [1][4].

Praktična posljedica je da se odabir terapije prve linije sada može temeljiti na razlozima, a ne na zadanom izboru, te su vidljive razlike između lijekova u indukciji naspram održavanja, kao i u učinkovitosti naspram sigurnosti.

Komparativna učinkovitost naprednih terapija

Skupine

Skupine napredne terapije u IBD-u
SkupinaMehanizamNapomene
Anti-TNFBlokira faktor nekroze tumora alfaNajduže iskustvo primjene; imunogenost je glavno ograničenje
Anti-integrinBlokira migraciju leukocita u crijevoSelektivan za crijevo, pa ima povoljan sustavni sigurnosni profil
Anti-IL-12/23 i anti-IL-23Blokira signalizaciju interleukinaSnažan profil učinkovitosti i sigurnosti u nedavnim usporedbama
JAK inhibitoriMala molekula, unutarstanična signalizacijaOralni i brzo djelujući; upozorenja na kardiovaskularne i tromboembolijske rizike
S1P modulatoriZadržava limfocite u limfnim čvorovimaOralni; noviji, manje dugoročnih podataka

Liječenje prema cilju, a ne prema simptomima

Najznačajnija promjena u liječenju IBD-a jest spoznaja da simptomi loše odražavaju upalu. Ljudi se mogu osjećati dobro uz aktivnu upalu, a loše u remisiji. Zbog toga se prema aktualnim europskim smjernicama ciljaju objektivni pokazatelji — fekalni kalprotektin, endoskopsko cijeljenje — a ne subjektivni osjećaj bolesnika.

To je također odgovor na pitanje o prehrani postavljeno na stranici o prehrani: intervencija koja poboljšava simptome bez poboljšanja objektivnih pokazatelja nije liječila bolest.

Kada jedan lijek nije dovoljan

Dvojna biološka terapija ili kombinirana terapija lijekovima malih molekula procijenjena je za refraktornu bolest [3]. Ona ostaje odluka specijalista s ograničenom bazom dokaza, i upravo je tu istraživanje na razini pojedinačnih stanica koje opisuje heterogenost odgovora [2] najvjerojatnije promijeniti kliničku praksu — predviđanjem koji mehanizam ciljati u određenog bolesnika, umjesto da se to otkriva uzastopnim neuspjesima terapije.

Pogled s ulice na zgradu kolodvorske ljekarne u Bautzenu, Njemačka
Fiver, der Hellseher · CC BY-SA 4.0 · Wikimedia Commons

Često postavljana pitanja

Koji je biološki lijek najbolji?
Mrežne meta-analize ih danas rangiraju [1][4], a pravi odabir ovisi o lokalizaciji bolesti, težini, ekstraintestinalnim manifestacijama i vlastitoj tolerantnosti na rizik.
Mogu li prestati uzimati lijek kada postignem remisiju?
Prekid terapije nosi znatan rizik relapsa. To je odluka koju treba donijeti zajedno s liječničkim timom, na temelju objektivnih pokazatelja, a ne osjećaja.
Jesu li biološki lijekovi opasni?
Nose stvarne rizike, prije svega rizik od infekcije. Neliječena upala također nosi rizik, pa se uspoređuju dva rizika, a ne rizik naspram nule.
Čemu služi kalprotektin?
To je marker crijevne upale u stolici. Upravo se njime u praksi prati provođenje pristupa "liječenje prema cilju".
Dokazi na kojima se temelji ova stranica Stupčasti grafikon koji prikazuje sastav 26 publikacija citiranih na ovoj stranici prema vrsti studije. 26meta-analysis (26)
26 publikacija, 2015. – 2025. Riječ je uglavnom o observacijskoj bazi dokaza. Ona može utvrditi da se stvari događaju zajedno; ne može utvrditi koja od njih uzrokuje drugu. Izvor: popis citata ove stranice, u nastavku.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  2. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  3. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  4. ACG Clinical Guideline Update: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701556
  5. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Afzali A, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701562
  6. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders Barnes EL, Agrawal M, Syal G, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38128971Full text
  7. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review Hashash JG, Elkins J, Lewis JD, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38276922
  8. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  9. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis Singh S, Loftus EV Jr, Limketkai BN, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 39572132Full text
  10. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment Adamina M, Minozzi S, Warusavitarne J, et al. · Journal of Crohn's & colitis · 2024 · Clinical guideline DOIPubMed 38878002
  11. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  12. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  13. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  14. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  15. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  16. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  17. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  18. [ESPEN guideline: Clinical nutrition in inflammatory bowel disease] Bischoff SC, Escher J, Hébuterne X, et al. · Nutricion hospitalaria · 2022 · Clinical guideline DOIPubMed 35014851
  19. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  20. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  21. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  22. ACG Clinical Guideline: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2019 · Clinical guideline DOIPubMed 30840605
  23. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Isaacs KL, et al. · The American journal of gastroenterology · 2018 · Clinical guideline DOIPubMed 29610508
  24. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition Turner D, Ruemmele FM, Orlanski-Meyer E, et al. · Journal of pediatric gastroenterology and nutrition · 2018 · Clinical guideline DOIPubMed 30044357
  25. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  26. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original